Jasper Therapeutics Q1 net loss widens to $14.3M; de-prioritizes AML/MDS Phase 3

Jasper Therapeutics, Inc.

2023-Q1 EPS reported -$0.16

Net loss of $14.3M in Q1 2023 vs $2.2M in Q1 2022, driven by increased R&D and warrant liability changes.
Cash and cash equivalents of $129.4M as of March 31, 2023, boosted by $101.4M net proceeds from January public offering.
De-prioritized Phase 3 development of briquilimab as conditioning for AML/high-risk MDS; now focusing on chronic spontaneous urticaria and low-intermediate risk MDS.
Announced positive clinical data from Phase I/II of briquilimab in sickle cell disease: all three patients engrafted, 100% donor myeloid chimerism at 60 days.
Strengthened board with Vishal Kapoor; appointed Daniel Adelman as Acting CMO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jasper Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $14.3 million.

Period: the quarter ended March 31, 2023
Net income: Net loss was $14.3 million
Result: reported results

Exact text from the filing

On May 12, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2023 and providing a business update.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-038997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.